• News
  • SAN DIEGO
  • General

La Jolla Pharmaceutical enters agreement with Stanford University

La Jolla Pharmaceutical Co. (Nasdaq: LJPC), a biotechnology company developing therapeutics targeting significant unmet diseases, announced Monday it has signed an option agreement with Stanford University that will add proprietary technology to the company’s programs.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

La Jolla Pharmaceutical Co.

Company Website

6455 Nancy Ridge Dr.
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
LJPC
20.15
  2.90  
+ 16.81%
704,073,000
20.41
6.17

Insider Trade Data

Date Insider Shares Type Value
12/16/2014 Tang, Kevin C 232,925 Purchase $2,992,446
12/15/2014 Tang, Kevin C 232,343 Purchase $2,984,330
12/11/2014 Tidmarsh, George F 4,000 Purchase $45,520
12/11/2014 Tidmarsh, George F 4,000 Purchase $45,520
07/31/2014 Zarrabian, Saiid 381 Purchase $3,631

La Jolla Pharmaceutical Co. Executive(s):

Deirdre Gillespie

  • Chief Executive Officer, President

George Tidmarsh

  • Chief Executive Officer, President

Similar Companies

NAICS - 325412 - Pharmaceutical Preparation Manufacturing
SIC - 2834 - PHARMACEUTICAL PREPARATIONS
SIC - 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
NAICS - 541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
SIC - 3769 - GUIDED MISSILE AND SPACE VEHICLE PARTS AND AUXILIARY EQUIPMENT, N
SIC - 3721 - AIRCRAFT
SIC - 3761 - GUIDED MISSILES AND SPACE VEHICLES
Subscribe Today!